Loading…

Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma

Background Cytokines, such as interleukins (IL)‐4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL‐4/IL‐13, inhibiting signaling. In this post hoc analysis of VOYAGE (NCT0294...

Full description

Saved in:
Bibliographic Details
Published in:Allergy (Copenhagen) 2023-08, Vol.78 (8), p.2157-2167
Main Authors: Papadopoulos, Nikolaos G., Szefler, Stanley J., Bacharier, Leonard B., Maspero, Jorge F., Domingo, Christian, Fiocchi, Alessandro, Lee, Jason K., Daizadeh, Nadia, Lederer, David J., Hardin, Megan, Gall, Rebecca, Djandji, Michel, Siddiqui, Shahid, Jacob‐Nara, Juby A., Deniz, Yamo, Rowe, Paul J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Cytokines, such as interleukins (IL)‐4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL‐4/IL‐13, inhibiting signaling. In this post hoc analysis of VOYAGE (NCT02948959), dupilumab efficacy was evaluated in patients aged 6–11 years with type 2 asthma with or without evidence of allergic asthma (baseline serum total IgE ≥30 IU/mL and ≥1 perennial aeroallergen‐specific IgE ≥0.35kU/L). Methods Annualized severe exacerbation rates (AER) and changes in pre‐bronchodilator (Pre‐BD) forced expiratory volume in one second (FEV1), percent‐predicted pre‐BD FEV1 (ppFEV1), and Asthma Control Score (ACQ)‐7 were assessed during the treatment period. Results 350 children (261 with and 89 without evidence of allergic asthma) were included. Dupilumab versus placebo significantly reduced AER in patients with (0.24 vs. 0.62, relative risk reduction [RRR]: 62% [95% CI, 39–76], P 
ISSN:0105-4538
1398-9995
DOI:10.1111/all.15743